Orthocell Limited Stock price

Equities

OCC

AU000000OCC6

Biotechnology & Medical Research

Market Closed - Australian S.E. 12:40:03 2024-03-28 am EDT 5-day change 1st Jan Change
0.39 AUD +0.65% Intraday chart for Orthocell Limited 0.00% -4.88%
Sales 2022 1.53M 998K Sales 2023 4.24M 2.76M Capitalization 69.06M 44.99M
Net income 2022 -9M -5.86M Net income 2023 -6M -3.91M EV / Sales 2022 45.3 x
Net cash position 2022 10.51M 6.85M Net cash position 2023 24.26M 15.8M EV / Sales 2023 10.6 x
P/E ratio 2022
-8.62 x
P/E ratio 2023
-10.9 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 74.74%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.65%
Current month-8.24%
1 month-9.30%
3 months-2.50%
6 months+6.85%
Current year-4.88%
More quotes
1 week
0.38
Extreme 0.38
0.41
1 month
0.38
Extreme 0.38
0.42
Current year
0.37
Extreme 0.37
0.45
1 year
0.32
Extreme 0.32
0.46
3 years
0.30
Extreme 0.3
0.66
5 years
0.11
Extreme 0.105
0.78
10 years
0.11
Extreme 0.105
0.99
More quotes
Managers TitleAgeSince
Founder - 06-03-20
Founder 58 06-03-20
Director of Finance/CFO - 06-02-28
Members of the board TitleAgeSince
Director/Board Member - 23-10-24
Chairman - 23-05-31
Director/Board Member - 23-03-07
More insiders
Date Price Change Volume
24-03-28 0.39 +0.65% 212,313
24-03-27 0.3875 +1.97% 2,529
24-03-26 0.38 -2.56% 235,934
24-03-25 0.39 -2.50% 143,728
24-03-22 0.4 +2.56% 34,872

Delayed Quote Australian S.E., March 28, 2024 at 12:40 am EDT

More quotes
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. It is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Orthocell Limited - Australian S.E.